Obesity: Liraglutide-another weapon in the war against obesity?

Nature Reviews Endocrinology

Volumn 11, Issue 10, 2015, Pages 569-570

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

BODY WEIGHT; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD INTAKE; GALLBLADDER DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; WEIGHT LOSS PROGRAM; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; FEMALE; MALE;

FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OBESITY;

EID: 84941874837     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.133     Document Type: Short Survey

References (10)

1. Pi-Sunyer X., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11-22 (2015
2. Sturm R., & Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int. J. Obes. 37, 889-891 (2013
3. Jensen M. D., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J. Am. Coll. Cardiol. 63 (25 Pt. B), 2985-3023 (2014
4. Bray G. A. in The Battle of the Bulge. (Dorrance Publishing, 2007
5. Hamman R. F. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29, 2102-2107 (2006
6. Simons-Morton D. G., Obarzanek E., & Cutler J. A. Obesity research-limitations of methods, measurements, and medications. JAMA 295, 826-828 (2006
7. The Look AHEAD Research Group; Wing R. R., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145-154 (2013
8. Bray G. A. Evaluation of drugs for treating obesity. Obes. Res. 3 (Suppl. 4), 425S-434S (1995
9. Sumithran P., et al. Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 365, 1597-1604 (2011
10. Foster G. D., Wadden T. A., Vogt R. A., & Brewer G. What is a reasonable weight loss?. Patients' expectations and evaluations of obesity treatment outcomes. J. Consult. Clin. Psychol. 65, 79-85 (1997